OBJECTIVE: To evaluate the impact of preoperative markers of systemic inflammation on complications and oncological outcomes in patients aged ≥75 years treated with radical cystectomy (RC) for urothelial bladder cancer (UBC). PATIENTS AND METHODS: The clinical data of 694 patients treated with open RC for UBC at our institution between January 2008 and December 2015 were retrospectively reviewed. Patients aged <75 years, with distant metastases, other-than-urothelial histological type, comorbidities that could affect the systemic inflammatory markers, and patients who received neoadjuvant chemotherapy were excluded. Multivariable regression models were built for the prediction of major postoperative surgical complications, disease recurrence, cancer-specific mortality (CSM), and overall mortality (OM). RESULTS: The median (interquartile range [IQR]) age at surgery was 79 (75-83) years. Major postoperative surgical complications were registered in 41.9% of the patients. The 5-year overall survival, cancer-specific survival and recurrence-free survival rates were 42.4% (95% confidence interval [CI] 34.7-49.9%), 70.3% (95% CI 62.3-76.9%), and 59.8% (95% CI 52.4-66.5), respectively. At multivariable analysis, higher levels of fibrinogen and a modified Glasgow Prognostic Score (mGPS) of 1 and 2 at baseline were independently associated with higher risk of major postoperative complications and of CSM. The inclusion of mGPS and fibrinogen to a standard multivariable model for recurrence and for CSM increased discrimination from 69.4% to 73.0% and from 71.3% to 73.9%, respectively. Preoperative neutrophil-to-lymphocyte ratio of >3 was independently associated with OM (hazard ratio 1.38, 95% CI 1.01-1.77; P = 0.01). CONCLUSIONS: In a cohort of elderly patients with UBC treated with RC, fibrinogen and mGPS appeared to be the most relevant prognostic measurements and increased the accuracy of clinicopathological preoperative models to predict major postoperative complications, disease recurrence and mortality. ABBREVIATIONS: ASA: American Society of Anesthesiologists; CCI: Charlson Comorbidity Index; CIS: carcinoma in situ; CRP: C-reactive protein; CSM: cancer-specific mortality; CSS: cancer-specific survival; ECOG PS: Eastern Cooperative Oncology Group Performance Status; HDL: high-density lipoprotein; (S)HR: (subdistribution) hazard ratio; LND: lymphadenectomy; LVI: lymphovascular invasion; mGPS: modified Glasgow Prognostic Score; NLR: neutrophil-to-lymphocyte ratio; NOC: non-organ-confined; OM: overall mortality; OR: odds ratio; OS: overall survival; RC: radical cystectomy; RNU: radical nephroureterectomy; UBC: urothelial bladder cancer; UTUC: upper urinary tract urothelial carcinoma.
OBJECTIVE: To evaluate the impact of preoperative markers of systemic inflammation on complications and oncological outcomes in patients aged ≥75 years treated with radical cystectomy (RC) for urothelial bladder cancer (UBC). PATIENTS AND METHODS: The clinical data of 694 patients treated with open RC for UBC at our institution between January 2008 and December 2015 were retrospectively reviewed. Patients aged <75 years, with distant metastases, other-than-urothelial histological type, comorbidities that could affect the systemic inflammatory markers, and patients who received neoadjuvant chemotherapy were excluded. Multivariable regression models were built for the prediction of major postoperative surgical complications, disease recurrence, cancer-specific mortality (CSM), and overall mortality (OM). RESULTS: The median (interquartile range [IQR]) age at surgery was 79 (75-83) years. Major postoperative surgical complications were registered in 41.9% of the patients. The 5-year overall survival, cancer-specific survival and recurrence-free survival rates were 42.4% (95% confidence interval [CI] 34.7-49.9%), 70.3% (95% CI 62.3-76.9%), and 59.8% (95% CI 52.4-66.5), respectively. At multivariable analysis, higher levels of fibrinogen and a modified Glasgow Prognostic Score (mGPS) of 1 and 2 at baseline were independently associated with higher risk of major postoperative complications and of CSM. The inclusion of mGPS and fibrinogen to a standard multivariable model for recurrence and for CSM increased discrimination from 69.4% to 73.0% and from 71.3% to 73.9%, respectively. Preoperative neutrophil-to-lymphocyte ratio of >3 was independently associated with OM (hazard ratio 1.38, 95% CI 1.01-1.77; P = 0.01). CONCLUSIONS: In a cohort of elderly patients with UBC treated with RC, fibrinogen and mGPS appeared to be the most relevant prognostic measurements and increased the accuracy of clinicopathological preoperative models to predict major postoperative complications, disease recurrence and mortality. ABBREVIATIONS: ASA: American Society of Anesthesiologists; CCI: Charlson Comorbidity Index; CIS: carcinoma in situ; CRP: C-reactive protein; CSM: cancer-specific mortality; CSS: cancer-specific survival; ECOG PS: Eastern Cooperative Oncology Group Performance Status; HDL: high-density lipoprotein; (S)HR: (subdistribution) hazard ratio; LND: lymphadenectomy; LVI: lymphovascular invasion; mGPS: modified Glasgow Prognostic Score; NLR: neutrophil-to-lymphocyte ratio; NOC: non-organ-confined; OM: overall mortality; OR: odds ratio; OS: overall survival; RC: radical cystectomy; RNU: radical nephroureterectomy; UBC: urothelial bladder cancer; UTUC: upper urinary tract urothelial carcinoma.
Authors: Martin J Magers; Antonio Lopez-Beltran; Rodolfo Montironi; Sean R Williamson; Hristos Z Kaimakliotis; Liang Cheng Journal: Histopathology Date: 2019-01 Impact factor: 5.087
Authors: David D Andrea; Mohammad Abufaraj; Martin Susani; Robin Ristl; Beat Foerster; Shoji Kimura; Andrea Mari; Francesco Soria; Alberto Briganti; Pierre I Karakiewicz; Killian M Gust; Morgan Rouprêt; Shahrokh F Shariat Journal: Urol Oncol Date: 2018-03-03 Impact factor: 3.498
Authors: Luis A Kluth; Peter C Black; Bernard H Bochner; James Catto; Seth P Lerner; Arnulf Stenzl; Richard Sylvester; Andrew J Vickers; Evanguelos Xylinas; Shahrokh F Shariat Journal: Eur Urol Date: 2015-02-21 Impact factor: 20.096
Authors: Anthony Linton; Greg Pond; Stephen Clarke; Janette Vardy; Matthew Galsky; Guru Sonpavde Journal: Clin Genitourin Cancer Date: 2013-06-28 Impact factor: 2.872
Authors: Ilaria Lucca; Patrice Jichlinski; Shahrokh F Shariat; Morgan Rouprêt; Malte Rieken; Luis A Kluth; Michael Rink; Romain Mathieu; Aurelie Mbeutcha; Agnes Maj-Hes; Harun Fajkovic; Alberto Briganti; Christian Seitz; Pierre I Karakiewicz; Michela de Martino; Yair Lotan; Marko Babjuk; Tobias Klatte Journal: Eur Urol Focus Date: 2015-05-29
Authors: Matteo Ferro; Ottavio De Cobelli; Carlo Buonerba; Giuseppe Di Lorenzo; Marco Capece; Dario Bruzzese; Riccardo Autorino; Danilo Bottero; Antonio Cioffi; Deliu Victor Matei; Michele Caraglia; Marco Borghesi; Ettore De Berardinis; Gian Maria Busetto; Riccardo Giovannone; Giuseppe Lucarelli; Pasquale Ditonno; Sisto Perdonà; Pierluigi Bove; Luigi Castaldo; Rodolfo Hurle; Gennaro Musi; Antonio Brescia; Michele Olivieri; Amelia Cimmino; Vincenzo Altieri; Rocco Damiano; Francesco Cantiello; Vincenzo Serretta; Sabino De Placido; Vincenzo Mirone; Guru Sonpavde; Daniela Terracciano Journal: Medicine (Baltimore) Date: 2015-10 Impact factor: 1.817
Authors: Damian Sudoł; Damian Widz; Przemysław Mitura; Paweł Płaza; Michał Godzisz; Iga Kuliniec; Andriy Yadlos; Michał Cabanek; Marek Bar; Krzysztof Bar Journal: Cent European J Urol Date: 2022-01-20